Insider buying last 90 days
No open-market insider purchases were filed for HALO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every HALO insider filing, plotted on the chart in Gekko.Open HALO in Gekko
NASDAQ: HALO
Halozyme Therapeutics (HALO) Stock Analysis & Forecast
Sep 28 close
$112.89−1.01 (−0.9%)
Gekko Brief
AI summaryHalozyme reached a new 52-week high this week, trading as high as $116.85, as investor optimism around its ENHANZE drug-delivery collaborations continued to build following record Q2 2026 results. The company also closed an upsized $1.5 billion offering of 1.50% Convertible Senior Notes due 2033, securing approximately $1.471 billion in net proceeds, with commentary noting the deal introduces new capital alongside potential future share dilution. Separate coverage highlighted the stock's long-term performance, noting a decade-old $1,000 investment would now be worth $9,284.68.
HALO closed at $112.89, down 0.9% on the day, with a close above both the 50-day average of $100.45 and the 200-day average of $77.39, and the 50-day above the 200-day. The GekkoIndex reads 51.4, placing the stock in the Neutral zone. Price sits 18.2% above Gekko Fair Value of $95.51, a gap the checklist flags as a headwind.
The next earnings report is due 2 November 2026, after the close, 34 days out and beyond a typical 20-trading-day hold; the prior report on 6 August 2026 produced a 23.4% reaction on a beat of $2.17 versus $1.73 estimated. No insider, Congress or unusual options activity appears in their respective windows. Seasonality over the next 20 trading days has averaged -4.6% across 5 years, rising in 1 of them, a figure worth noting alongside the current fair-value gap.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Halozyme Therapeutics price vs fair value
Close $112.89200-day averageGekko Fair Value $95.51
Halozyme Therapeutics quick facts
- Market cap
- $13.39B
- P/E ratio
- 33.4
- Forward P/E
- 11.5
- EPS, TTM
- $3.41
- Revenue, TTM
- $1.66B
- Profit margin
- 24.9%
- Dividend yield
- —
- Beta
- 0.88
- Volume
- 2.24M avg 2.24M
- 1-year return
- +52.6%
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±8.6%
- 50-day average
- $100.45
- 200-day average
- $77.39
- Next earnings
- Nov 2 after close
- Shares outstanding
- 113.5M
Halozyme Therapeutics swing-trade checklist
Halozyme Therapeutics scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $112.89 is above the 50-day ($100.45) and 200-day ($77.39) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
51.4, Neutral
Reading 51.4 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
18.2% above
Price is 18.2% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 34 days
Next report Nov 2, 2026, 34 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−4.6% on average
From this point in the calendar, the next 20 trading days averaged −4.6% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Halozyme Therapeutics stock chart and price history
Halozyme Therapeutics closed at $112.89 on Sep 28, 2026, +52.6% over the past year, inside a 52-week range of $61.23 to $116.85.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +5.6%
- 3 months
- +46.3%
- 6 months
- +83.2%
- 1 year
- +52.6%
The full HALO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open HALO in Gekko
Follow Halozyme Therapeutics through every session
Put HALO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track HALO in GekkoFree for 7 days. No credit card required.
About Halozyme Therapeutics
Halozyme Therapeutics develops technology that helps deliver injectable medicines beneath the skin rather than through longer infusions. Its central offering, ENHANZE, is built around a patented enzyme called rHuPH20 that makes it easier for biologics, antibodies, smaller drug compounds and fluids to be absorbed subcutaneously. The company is also known for Hylenex recombinant, an rHuPH20-based product used to support subcutaneous fluid delivery for hydration and to assist dispersion and absorption of other injected drugs.
Beyond its own products, Halozyme licenses its delivery platform to other pharmaceutical makers, whose treatments for conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia and immunodeficiency disorders incorporate the technology. Its pipeline work extends to investigational treatments for cancers, multiple sclerosis, myeloma and autoimmune disease, developed through partnerships with companies including Roche, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics, as well as with research bodies working on HIV treatment and prevention.
Halozyme Therapeutics is headquartered in San Diego, California, with operations across the United States, Switzerland, Ireland, Belgium, Japan and other markets, and was founded in 1998. Its shares are listed on the NASDAQ under the ticker HALO.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- halozyme.com
Halozyme Therapeutics GekkoIndex: the smart money zone
Halozyme Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.4, in the Neutral zone, up 5.9 points over five sessions.
51.4Neutral
Up 5.9 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 30 | +2.9% | +11.8% | ||
| Accumulation | 179 | +1.1% | +4.3% | ||
| Neutral (current zone) | 386 | +0.8% | +3.5% | ||
| Distribution | 73 | +2.0% | +4.2% | ||
| Selling | 4 | Too few readings yet | |||
Average HALO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the HALO price, zone by zone.Track HALO in Gekko
Is Halozyme Therapeutics stock overvalued? Gekko Fair Value
Halozyme Therapeutics trades 18.2% above Gekko Fair Value of $95.51, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Halozyme Therapeutics shares are worth, recalculated every trading day.
$95.51
Gekko Fair Value, Sep 29, 2026
18.2% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open HALO in Gekko
Halozyme Therapeutics insider and Congress trading
No open-market insider purchases were filed for Halozyme Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in HALO were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for HALO, plotted on the chart in Gekko.Open HALO in Gekko
Buybacks
Halozyme Therapeutics has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $332.7M
- As a share of market cap
- 2.48%
From company filings.
Halozyme Therapeutics earnings: next date and track record
Halozyme Therapeutics reports on Nov 2, 2026, after the close (34 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 2, 2026
Expected after the close, 34 days away
- EPS estimate
- $2.25
- Revenue estimate
- $482.3M
6 of 8reports beat the EPS estimate
±10%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Halozyme reported record Q2 2026 results with total revenue up 48% YoY to $481M, driven by royalty revenue growth of 50% YoY to $308M. Key contributors included Opdivo SC, Ocrevus SC, and Rybrevant SC with 80% QoQ growth. The company signed five new collaboration agreements in Q2/July for ENHANZE and Hypercon platforms, generating $35.5M in upfront revenue. Adjusted EBITDA reached $329M at 65%+ margins with non-GAAP EPS of $2.28.
- Guidance
- Halozyme raised full year 2026 guidance, increasing total revenue guidance by $110M based on strong royalty revenue momentum. Management expressed conviction in 2026-2028 financial targets and cited expanding partnerships and pipeline programs as drivers for 2029 and beyond.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $2.17 est $1.73 | $481.0M est $402.3M | +23.4% |
| May 11, 2026 | $1.22 est $1.76 | $376.7M est $358.6M | +10.6% |
| Feb 17, 2026 | −$0.24 est $2.20 | $451.8M est $435.7M | −7.8% |
| Nov 3, 2025 | $1.72 est $1.63 | $354.3M est $446.5M | +4.4% |
| Aug 5, 2025 | $1.54 est $1.23 | $325.7M est $330.8M | +3.9% |
| May 6, 2025 | $1.11 est $0.95 | $264.9M est $281.0M | +15.7% |
| Feb 18, 2025 | $1.26 est $1.16 | $298.0M est $285.7M | −0.9% |
| Oct 31, 2024 | $1.27 est $0.98 | $290.1M est $292.8M | +13.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Halozyme Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Halozyme Therapeutics is $99.56, −11.8% from the last close, from 6 firms rating the stock in the last 90 days.
$99.56consensus 12-month target, −11.8% from the last close
Now $112.89Avg $99.56
Low $93High $115
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 3 | H.C. Wainwright | $115 | +1.9% |
| Sep 2 | H.C. Wainwright | $115 | +1.9% |
| Aug 17 | H.C. Wainwright | $115 | +1.9% |
| Aug 7 | Morgan Stanley | $105 | −7.0% |
| Aug 7 | Wells Fargo | $95 | −15.8% |
+3.5%average 20-day move after past Neutral readings
−4.6%average move over the next 20 trading days in the last 5 years
±2.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Halozyme Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Halozyme Therapeutics averaged −4.6% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.6% | 2 of 5 |
| Next 10 trading days | −3.9% | 1 of 5 |
| Next 15 trading days | −3.5% | 1 of 5 |
| Next 20 trading days | −4.6% | 1 of 5 |
| Next 30 trading days | +5.7% | 2 of 5 |
For scale, HALO’s typical 20-trading-day move in either direction is about 8.6%.
Halozyme Therapeutics market cap and key statistics
Halozyme Therapeutics’s market cap is $13.39B, with a P/E ratio of 33.4 and revenue of $1.66B over the last twelve months.
Valuation
- Market cap
- $13.39B
- P/E ratio
- 33.4
- Forward P/E
- 11.5
- EPS, TTM
- $3.41
- Gekko Fair Value
- $95.51
Trading
- Volume
- 2.24M
- Avg volume, 20 days
- 2.24M
- 52-week high
- $116.85
- 52-week low
- $61.23
- Shares outstanding
- 113.5M
Financials
- Revenue, TTM
- $1.66B
- Profit margin
- 24.9%
- Return on equity
- 173.7%
- Quarterly earnings growth, YoY
- +42.9%
Risk and income
- Beta
- 0.88
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±8.6%
Halozyme Therapeutics stock news this week
Coverage of Halozyme Therapeutics this week reads positive: 4 positive, 2 neutral and 0 negative headlines.
- If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth NowEastern Progress, Sep 27
- Halozyme Therapeutics (HALO) Closes A US$1.3b Note Offering, Is The Upside Already Priced In?Simply Wall Street, Sep 24
- Halozyme Therapeutics (NASDAQ:HALO) Reaches New 12-Month High – Here’s WhyDefense World, Sep 24
- Head to Head Review: Halozyme Therapeutics (NASDAQ:HALO) & Co-Diagnostics (NASDAQ:CODX)Defense World, Sep 24
- Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?Yahoo Finance, Sep 23
- Halozyme Therapeutics Raises $1.5 Billion in 1.50% Convertible Notes, Adds Capped CallsTradingView, Sep 22
Halozyme Therapeutics peers
Halozyme Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Halozyme Therapeutics stock FAQ
What is Halozyme Therapeutics’s market cap?
Halozyme Therapeutics’s market cap is $13.39B at the Sep 28, 2026 close of $112.89, with 113.5M shares outstanding. The shares trade on a P/E ratio of 33.4.
What is the Halozyme Therapeutics stock forecast?
The consensus analyst 12-month price target for Halozyme Therapeutics is $99.56, −11.8% from the last close. Of the 6 firms that rated the stock in the last 90 days, 5 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Halozyme Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Halozyme Therapeutics is overvalued: the Sep 28, 2026 close of $112.89 is 18.2% above Gekko Fair Value of $95.51. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Halozyme Therapeutics report earnings next?
Halozyme Therapeutics is expected to report on Nov 2, 2026, after the market closes (34 days away). Analysts expect earnings of $2.25 per share on revenue of $482.3M. Halozyme Therapeutics beat the earnings estimate in 6 of its last 8 reports, moving 10% on average across the report.
What is Halozyme Therapeutics’s 52-week high and low?
Halozyme Therapeutics’s 52-week high is $116.85 and its 52-week low is $61.23; it closed at $112.89 on Sep 28, 2026, +52.6% over the past year.
Is Halozyme Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Halozyme Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.